000282559 001__ 282559
000282559 005__ 20251202141200.0
000282559 0247_ $$2doi$$a10.1177/13872877251379083
000282559 0247_ $$2pmid$$apmid:41234025
000282559 0247_ $$2pmc$$apmc:PMC12647378
000282559 0247_ $$2ISSN$$a1387-2877
000282559 0247_ $$2ISSN$$a1875-8908
000282559 037__ $$aDZNE-2025-01322
000282559 041__ $$aEnglish
000282559 082__ $$a610
000282559 1001_ $$aOomens, Julie E$$b0
000282559 245__ $$aAssociations of lifestyle factors with amyloid pathology in persons without dementia.
000282559 260__ $$aAmsterdam$$bIOS Press$$c2025
000282559 3367_ $$2DRIVER$$aarticle
000282559 3367_ $$2DataCite$$aOutput Types/Journal article
000282559 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1764680897_28228
000282559 3367_ $$2BibTeX$$aARTICLE
000282559 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282559 3367_ $$00$$2EndNote$$aJournal Article
000282559 520__ $$aBackgroundThe association between lifestyle factors and Alzheimer's disease (AD) pathophysiology remains incompletely understood.ObjectiveThe aim of this study was to assess the association of alcohol consumption, smoking behavior, sleep quality and physical, cognitive, and social activity with cerebral amyloid pathology.MethodsFor this cross-sectional study, we selected participants from the Amyloid Biomarker Study data pooling initiative. We used generalized estimating equations to assess associations of dichotomized lifestyle measures with amyloid pathology.ResultsWe included 9171 participants with normal cognition (NC) and 2555 participants with mild cognitive impairment (MCI) from the Amyloid Biomarker Study. Of participants with NC, 58% were women, 34% were APOE ε4 carrier, and 27% had amyloid pathology. Of participants with MCI, 48% were women, 47% were APOE ε4 carrier, and 57% had amyloid pathology. In NC, cognitively active participants were less likely to have amyloid pathology (OR = 0.77, 95%CI 0.66-0.89, p < 0.001). In MCI, participants who had ever smoked or had sleep problems were less likely to have amyloid pathology (OR = 0.85, 95%CI 0.73-0.99, p = 0.029; OR = 0.62, 95%CI 0.45-0.86, p = 0.004).ConclusionsIn NC, cognitive activity was associated with a lower frequency of amyloid pathology. In MCI, favorable lifestyle behaviors were not associated with a lower frequency of amyloid pathology. The results of the current study contribute to the broader evidence base on lifestyle and AD by further characterizing the role of lifestyle behaviors in AD pathology across different clinical stages.
000282559 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000282559 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000282559 650_7 $$2Other$$aAlzheimer's disease
000282559 650_7 $$2Other$$aamyloid
000282559 650_7 $$2Other$$aamyloid biomarker study
000282559 650_7 $$2Other$$acerebrospinal fluid
000282559 650_7 $$2Other$$alifestyle
000282559 650_7 $$2Other$$apositron emission tomography
000282559 650_7 $$2NLM Chemicals$$aAmyloid
000282559 650_7 $$2NLM Chemicals$$aApolipoprotein E4
000282559 650_2 $$2MeSH$$aHumans
000282559 650_2 $$2MeSH$$aFemale
000282559 650_2 $$2MeSH$$aMale
000282559 650_2 $$2MeSH$$aAged
000282559 650_2 $$2MeSH$$aLife Style
000282559 650_2 $$2MeSH$$aCross-Sectional Studies
000282559 650_2 $$2MeSH$$aCognitive Dysfunction: pathology
000282559 650_2 $$2MeSH$$aCognitive Dysfunction: psychology
000282559 650_2 $$2MeSH$$aCognitive Dysfunction: metabolism
000282559 650_2 $$2MeSH$$aCognitive Dysfunction: genetics
000282559 650_2 $$2MeSH$$aAged, 80 and over
000282559 650_2 $$2MeSH$$aAlcohol Drinking
000282559 650_2 $$2MeSH$$aSmoking
000282559 650_2 $$2MeSH$$aMiddle Aged
000282559 650_2 $$2MeSH$$aAmyloid: metabolism
000282559 650_2 $$2MeSH$$aApolipoprotein E4: genetics
000282559 650_2 $$2MeSH$$aDementia
000282559 7001_ $$aVos, Stephanie Jb$$b1
000282559 7001_ $$aMaserejian, Nancy N$$b2
000282559 7001_ $$aBoada, Mercè$$b3
000282559 7001_ $$aDidic, Mira$$b4
000282559 7001_ $$aEngelborghs, Sebastiaan$$b5
000282559 7001_ $$aFladby, Tormod$$b6
000282559 7001_ $$avan der Flier, Wiesje M$$b7
000282559 7001_ $$aFrisoni, Giovanni B$$b8
000282559 7001_ $$aFröhlich, Lutz$$b9
000282559 7001_ $$aGill, Kiran Dip$$b10
000282559 7001_ $$aGrimmer, Timo$$b11
000282559 7001_ $$aHort, Jakub$$b12
000282559 7001_ $$aItoh, Yoshiaki$$b13
000282559 7001_ $$aIwatsubo, Takeshi$$b14
000282559 7001_ $$aKlimkowicz-Mrowiec, Aleksandra$$b15
000282559 7001_ $$aLandau, Susan M$$b16
000282559 7001_ $$aLee, Dong Young$$b17
000282559 7001_ $$aLleó, Alberto$$b18
000282559 7001_ $$aMartinez-Lage, Pablo$$b19
000282559 7001_ $$ade Mendonça, Alexandre$$b20
000282559 7001_ $$aMeyer, Philipp T$$b21
000282559 7001_ $$aParchi, Piero$$b22
000282559 7001_ $$aPardini, Matteo$$b23
000282559 7001_ $$aParnetti, Lucilla$$b24
000282559 7001_ $$aPopp, Julius$$b25
000282559 7001_ $$aRami, Lorena$$b26
000282559 7001_ $$aReiman, Eric M$$b27
000282559 7001_ $$aRinne, Juha O$$b28
000282559 7001_ $$aRodrigue, Karen M$$b29
000282559 7001_ $$aSánchez-Juan, Pascual$$b30
000282559 7001_ $$aSantana, Isabel$$b31
000282559 7001_ $$aScarmeas, Nikolaos$$b32
000282559 7001_ $$aScheltens, Philip$$b33
000282559 7001_ $$aSkoog, Ingmar$$b34
000282559 7001_ $$aSperling, Reisa A$$b35
000282559 7001_ $$aStern, Yaakov$$b36
000282559 7001_ $$aVilleneuve, Sylvia$$b37
000282559 7001_ $$aWaldemar, Gunhild$$b38
000282559 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b39$$udzne
000282559 7001_ $$aZetterberg, Henrik$$b40
000282559 7001_ $$aAlcolea, Daniel$$b41
000282559 7001_ $$aAllegri, Ricardo F$$b42
000282559 7001_ $$aAltomare, Daniele$$b43
000282559 7001_ $$aBateman, Randall J$$b44
000282559 7001_ $$aBaiardi, Simone$$b45
000282559 7001_ $$aBaldeiras, Ines$$b46
000282559 7001_ $$aBlennow, Kaj$$b47
000282559 7001_ $$aBraber, Anouk den$$b48
000282559 7001_ $$avan Buchem, Mark A$$b49
000282559 7001_ $$aByun, Min Soo$$b50
000282559 7001_ $$aCerman, Jiří$$b51
000282559 7001_ $$aChen, Kewei$$b52
000282559 7001_ $$aChipi, Elena$$b53
000282559 7001_ $$aDay, Gregory S$$b54
000282559 7001_ $$0P:(DE-2719)2811239$$aDrzezga, Alexander$$b55$$udzne
000282559 7001_ $$aEkblad, Laura L$$b56
000282559 7001_ $$aFörster, Stefan$$b57
000282559 7001_ $$aFortea, Juan$$b58
000282559 7001_ $$aFreund-Levi, Yvonne$$b59
000282559 7001_ $$aFrings, Lars$$b60
000282559 7001_ $$aGuedj, Eric$$b61
000282559 7001_ $$aHabeck, Christian G$$b62
000282559 7001_ $$aHandels, Ron$$b63
000282559 7001_ $$aHausner, Lucrezia$$b64
000282559 7001_ $$aHellwig, Sabine$$b65
000282559 7001_ $$aJiménez-Bonilla, Julio F$$b66
000282559 7001_ $$aJuaristi, Ane Iriondo$$b67
000282559 7001_ $$aKandimalla, Ramesh$$b68
000282559 7001_ $$aKern, Silke$$b69
000282559 7001_ $$aBordewick Kirsebom, Bjørn-Eivind S$$b70
000282559 7001_ $$aKornhuber, Johannes$$b71
000282559 7001_ $$aLegdeur, Nienke$$b72
000282559 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b73$$udzne
000282559 7001_ $$aMaier, Wolfgang$$b74
000282559 7001_ $$aMarquié, Marta$$b75
000282559 7001_ $$aMinatani, Shinobu$$b76
000282559 7001_ $$aMorbelli, Silvia Daniela$$b77
000282559 7001_ $$aMroczko, Barbara$$b78
000282559 7001_ $$aNtanasi, Eva$$b79
000282559 7001_ $$ade Oliveira, Catarina Resende$$b80
000282559 7001_ $$aOrellana, Adelina$$b81
000282559 7001_ $$0P:(DE-2719)2811024$$aPeters, Oliver$$b82$$udzne
000282559 7001_ $$aPrabhakar, Sudesh$$b83
000282559 7001_ $$aRamakers, Inez H$$b84
000282559 7001_ $$aRodríguez-Rodriguez, Eloy$$b85
000282559 7001_ $$aRuiz, Agustín$$b86
000282559 7001_ $$aRüther, Eckart$$b87
000282559 7001_ $$aSakhardande, Jayant$$b88
000282559 7001_ $$aSelnes, Per$$b89
000282559 7001_ $$aSilva, Dina$$b90
000282559 7001_ $$aSoininen, Hilkka$$b91
000282559 7001_ $$aSpiru, Luiza$$b92
000282559 7001_ $$aTakeda, Akitoshi$$b93
000282559 7001_ $$aTeunissen, Charlotte E$$b94
000282559 7001_ $$aTijms, Betty M$$b95
000282559 7001_ $$aVermunt, Lisa$$b96
000282559 7001_ $$aWallin, Åsa K$$b97
000282559 7001_ $$aWiels, Wietse$$b98
000282559 7001_ $$aYannakoulia, Mary$$b99
000282559 7001_ $$aYi, Dahyun$$b100
000282559 7001_ $$aZettergren, Anna$$b101
000282559 7001_ $$aInitiative, Alzheimer's Disease Neuroimaging$$b102$$eCollaboration Author
000282559 7001_ $$agroup, A4 Study$$b103$$eCollaboration Author
000282559 7001_ $$aNetwork, Dominantly Inherited Alzheimer$$b104$$eCollaboration Author
000282559 7001_ $$aDementia, European Prevention of Alzheimer's$$b105$$eCollaboration Author
000282559 7001_ $$aJapan Alzheimer's Disease Neuroimaging Initiative , Korean Brain Aging Study$$b106$$eJ-ADNI
000282559 7001_ $$aDisease, Prediction of Alzheimer's$$b107$$eCollaboration Author
000282559 7001_ $$aDisease, Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer's$$b108$$eCollaboration Author
000282559 7001_ $$aOssenkoppele, Rik$$b109
000282559 7001_ $$aVerhey, Frans Rj$$b110
000282559 7001_ $$aVisser, Pieter Jelle$$b111
000282559 7001_ $$aJansen, Willemijn J$$b112
000282559 7001_ $$aEarly Diagnosis$$b113$$eCollaboration author
000282559 773__ $$0PERI:(DE-600)2070772-1$$a10.1177/13872877251379083$$gVol. 108, no. 3, p. 1043 - 1059$$n3$$p1043 - 1059$$tJournal of Alzheimer's disease$$v108$$x1387-2877$$y2025
000282559 8564_ $$uhttps://pub.dzne.de/record/282559/files/DZNE-2025-01322.pdf$$yRestricted
000282559 8564_ $$uhttps://pub.dzne.de/record/282559/files/DZNE-2025-01322.pdf?subformat=pdfa$$xpdfa$$yRestricted
000282559 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811317$$aExternal Institute$$b39$$kExtern
000282559 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811239$$aExternal Institute$$b55$$kExtern
000282559 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b73$$kDZNE
000282559 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811024$$aExternal Institute$$b82$$kExtern
000282559 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000282559 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-20
000282559 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-20
000282559 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-20
000282559 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-20
000282559 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-20
000282559 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-20
000282559 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-20
000282559 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-20
000282559 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-20
000282559 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-20
000282559 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-20
000282559 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000282559 9201_ $$0I:(DE-2719)1111016$$kAG Levin$$lClinical Neurodegeneration$$x1
000282559 980__ $$ajournal
000282559 980__ $$aEDITORS
000282559 980__ $$aVDBINPRINT
000282559 980__ $$aI:(DE-2719)1111015
000282559 980__ $$aI:(DE-2719)1111016
000282559 980__ $$aUNRESTRICTED